Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**AmnioBoost** is a minimally processed amniotic fluid supplement derived from amniotic fluid collected from healthy donors during C-section deliveries, containing stem cells, growth factors, cytokines, hyaluronic acid, protease inhibitors, and anti-inflammatory proteins. It is injected into damaged tissues to reduce inflammation, stimulate tissue regeneration, enhance joint lubrication, and support structural healing by triggering the body's natural repair response. Originally developed by Lattice Biologics for chronic inflammatory conditions like osteoarthritis, it has been explored for joint pain, tendon injuries, peripheral neuropathy, and severe acute respiratory syndrome related to COVID-19, though it received FDA warning letters for unapproved COVID-19 claims and remains investigational for most uses.[3][5][9][11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AmnioBoost.